Consultation on potential Ebola therapies and vaccines 4‐5 September 2014 Geneva, Starling Hotel List of participants: 1. Dr Marylyn Addo, Professor of Emerging Infections, Universitätsklinikum Hamburg‐Eppendorf, German Center of Infectious Diseases Research (DZIF), Hamburg, Germany 2. Dr Clement Adebamowo, Chairman, National Health Research Ethics Committee of Nigeria, Federal Ministry of Health, Abuja, Nigeria 3. Dr Selidji Agnandji, Franceville, Gabon 4. Dr Enrica Alteri, Head of Safety and Efficacy of Medicines, Human Medicines Development and Evaluation Unit, European Medicines Agency, London, United Kingdom of Great Britain & Northern Ireland 5. Dr Sylvain Baize, Biology of Viral Emerging Infections, Institut Pasteur, Paris, France 6. Dr Younoussa Ballo, Secrétaire general, Ministère de la Santé, Conakry, Guinea 7. Dr Ripley Ballou, GlaxoSmithKline Biologicals SA, Rixensart, Belgium 8. Ms Helia Baradarani, Tekmira’s Manager of Medical Countermeasure Business Development, Vancouver, Canada 9. Dr Jarbas Barbosa, Vice Minister, Ministry of Health, Brasilia, Brazil 10. Dr Jesus Barral‐Guerin, Senior Manager, Vaccine Centre, Supply Division, UNICEF, Copenhagen, Denmark 11. Dr Daniel Bausch, Associate Professor, Department of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine, New Orleans, USA 12. Dr Sina Bavari, CIV US Army Medcom USA MRIID, USA 13. Dr Stephan Becker, Direktor, Institut für Virologie, Marburg, Germany 14. Dr Laetitia Bigger, Senior Manager, Vaccines Policy, IFPMA, Geneva, Switzerland 15. Dr Fred Binka, Vice Chanceller, University of Health and Allied Sciences, Ho, Ghana 16. Dr Francisco Blanco, Chief of Medicines & Nutrition, Supply Division, UNICEF, Copenhagen, Denmark 17. Dr Luciana Borio, Director, Office of Counterterrorism and Emerging Threats (OCET) in the Office of the Chief Scientist, U.S. Food and Drug Administration (FDA), Rockville, USA Consultation on potential Ebola therapies and vaccines 4‐5 September 2014 Geneva, Starling Hotel, Room Montana 18. Dr Abdullah Brooks, Centre for Health and Population Research, Dhaka, Bangladesh 19. Dr Philippe Calain, Unité de Recherche sur les Enjeux et Pratiques humanitaires (UREPH), Médecins sans Frontières, Geneva, Switzerland 20. Dr Michael Callahan, Command Physician, Rescue Medicine/Réseau Médical Patient Filovirus, Kinsasha, Harvard Medical School, Massachusetts General Hospital, Boston, USA 21. Dr Benoit Callendret, Crucell, Leiden, Netherlands 22. Dr Iris Chang, Hong Kong Academy of Pharmacy, Hong Kong, People’s Republic of China 23. Dr George Christopher, Chief Medical Officer, Joint Project Manager – Medical Countermeasure Systems, Department of Defense, Rockville, USA 24. Dr Supamit Chunsuttiwat, Senior Medical Officer, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand 25. Dr Jacob Cohn, Bavarian Nordic A/S, Kvistgaard, Denmark 26. Dr Christoph Conrad, Paul‐Ehrlich‐Institut, Langen, Germany 27. Mr Stephan Cook, Vice President, Vaccine Global Regulatory Affairs, Vaccine Value & Health Science, GlaxoSmithKline Biologicals SA, Rixensart, Belgium 28. Dr Marion Danis, Head, Section on Ethics and Health Policy, NIH, Bethesda, USA 29. Prof Jean‐François Delfraissy, Director of Agence nationale de Recherche (ANRS), Paris, France 30. Dr Martin de Smet, Médecins sans Frontières, Brussels, Belgium 31. Dr Antal Tal Dia, Chairman, National Immunization Technical Advisory Group (NITAG) Senegal, Dakar, Senegal 32. Dr Alpha Amadou Diallo, Rapporteur du Comité national d’Ethique et de Recherche en Santé, Conakry, Guinea 33. Prof Ousmane Doumbia, Secrétaire general, Ministère de la Santé et del'Hygiène publique, Bamako, Mali 34. Dr Karifa Douno, Chef, Division Etablissements biopharmaceutiques, Ministère de la Santé, Conakry, Guinea 35. Dr Mattias Egger, Professor of Epidemiology and Public Health, University of Bern, Bern, Switzerland 2 Consultation on potential Ebola therapies and vaccines 4‐5 September 2014 Geneva, Starling Hotel, Room Montana 36. Dr Lindsay Elmgren, Director, Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Canada 37. Dr Carol Epstein, MediVector, Inc. Fujifilm Pharmaceuticals USA, Boston, USA 38. Dr Jeremy Farrar, Director, Wellcome Trust, London, United Kingdom of Great Britain & Northern Ireland 39. Dr Patricia Fast, International AIDS Vaccine Initiative, New York, USA 40. Dr Eleanor Fish, University of Toronto, Toronto, Canada 41. Prof Fu Gao, Deputy Director General for sciences, China CDC, Beijing, China 42. Dr Jennifer Gibson, Director, Joint Centre for Bioethics, Director, World Health Organization Collaborating Centre for Bioethics, Associate Professor, Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, Canada 43. Dr Dennis Giesing, Vice President, Preclinical Research, MediVector, Inc. Fujifilm Pharmaceuticals USA, Boston, USA 44. Dr Jesse Goodman, George Town University, Washington, USA 45. Dr Barney Graham, Vaccine Research Centre, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA 46. Dr Nyankoye Haba, National Blood Service, Conakry, Guinea 47. Dr Fred Hayden, University of Virginia/WHO consultant, Charlottesville, USA 48. Dr Lisa Hensley, National Institute of Allergy and Infectious Diseases, NIH , Bethesda, USA 49. Dr Elizabeth Higgs, Global Health Science Advisor, Office of the Director, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA 50. Dr David Hone, Chief, Vaccine Branch, Research and Development Directorate (J9), Defense Threat Reduction Agency (DTRA), Department of Defense, Fort Belvoir, USA 51. Dr Peter Horby, University of Oxford, Oxford, United Kingdom of Great Britain & Northern Ireland 52. Dr Angela Huttner, Infection Control Programme, University Hospitals of Geneva, Switzerland 53. Dr Ryuichi Ida, Member of the Expert Panel on Bioethics (National Bioethics Committee), Kyoto, Japan 3 Consultation on potential Ebola therapies and vaccines 4‐5 September 2014 Geneva, Starling Hotel, Room Montana 54. Dr Giuseppe Ippolito, Scientific Director, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy 55. Dr Ambrose Isah, GACVS representative, Benin City, Nigeria 56. Dr Aikichi Iwamoto, The Institute of Medical Sciences, Research Center for Asian Infectious Diseases, Japan 57. Dr Amandua Jacinto, Commissioner Clinical Services, Ministry of Health and Social Welfare, Kampala, Uganda 58. Mrs Markieu Janneh‐Kaira, Chief Pharmacist/ Registrar, National Pharmaceutical Services, Ministry of Health & Social Welfare, Banjul, The Gambia 59. Dr Franca Jones, Medical Director, Chemical and Biological Defense Program, Office of the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs OASD(NCB/CB), Rockville, USA 60. Mrs Markieu Janneh‐Kaira, Chief Pharmacist/ Registrar, National Pharmaceutical Services, Ministry of Health and Social Welfare, Banjul, The Gambia 61. Ms Sadia Kaenzig, Manager, Communications, IFPMA, Geneva Switzerland 62. Dr Robinah Kaitiritimba, Uganda National Health Consumers' Organisation (UNHCO), Kampala Uganda 63. Dr Samuel Kargbo, Director, Reproductive and Child Health, Ministry of Health and Sanitation, Freetown, Sierra Leone 64. Dr Christopher Karp, Deputy Director, Discovery and Translational Sciences, Bill & Melinda Gates Foundation, Seattle, USA 65. Dr Francis N. Kateh, Medical Director / CEO, Jackson F. Doe Memorial Regional Referral Hospital, Tappita City, Lower Nimba County, Liberia 66. Dr Steve Kern, Deputy Director, Integrated Development, Bill & Melinda Gates Foundation, Seattle, USA 67. Dr Nadia Khelef, Institut Pasteur, Paris, France 68. Dr Hiroshi Kitaguchi, General Manager, Business Development Department, Toyama Chemical Co., Ltd., Tokyo, Japan 69. Dr Gary Kobinger, Public Health Agency of Canada, Vancouver, Canada 70. Dr Daniel Koch, Federal Office of Public Health, Bern, Switzerland 4 Consultation on potential Ebola therapies and vaccines 4‐5 September 2014 Geneva, Starling Hotel, Room Montana 71. Dr Mandy Kader Kondé, Président de la Commission Recherche Ebola, Conakry, Guinea 72. Dr Bocar Kouyate, Office of the Minister of Health, Ouagadougou, Burkina Faso 73. Dr Sanjeev Krishna, London, United Kingdom of Great Britain & Northern Ireland 74. Dr Michael Kurilla, Director, Office of BioDefense, Research Resources, and Translational Research, Associate Director for BioDefense Product Development, NIAID, NIH, Rockville, USA 75. Dr Randall Lanier, Executive Director of Biology, Chimerix Inc., Durham, USA 76. Dr James Lawler, Director, ACESO/Clinical Research Partner in Uganda, Kampala, Uganda 77. Dr Robert Lenk, EVP and CSO, MediVector, Boston, USA 78. Dr Bertand Lepine, FabEntech, Lyon, France 79. Dr Mike Levine, Director, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, USA 80. Dr Nicole Lurie, Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services, Washington, USA 81. Dr Ian MacLachlan, Executive Vice President and Chief Technical Officer, Tekmira Pharmaceuticals Corp., Vancouver, Canada 82. Dr Alan Magill, Director, Malaria, Bill & Melinda Gates Foundation, Seattle, USA 83. Prof Denis Malvy, Professor in Infectious Diseases, Bordeaux, France 84. Dr Brian K. Martin, Director, Infectious Disease Division, BioProtection Systems, a wholly‐owned subsidiary of NewLink Genetics, Ames, USA 85. Dr Jacques‐François Martin, Fab Entech, Lyon,